Status:
COMPLETED
Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Conditions:
Stage 0/1 Breast Cancer
Post Biopsy
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
NAC is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement and also is available as an injectable pharmaceutical that protects the liv...
Eligibility Criteria
Inclusion
- Demographic • Females ≥18 years of age
- Disease related
- Stage 0/I breast cancer by biopsy (patients may be consented and screened with suspected breast cancer, but no treatment will occur until cancer is confirmed by their biopsy).
- Awaiting surgery which will consist of either lumpectomy or mastectomy.
- ECOG performance status 0-1
- Laboratory
- Laboratory values that would not prevent the patient from receiving treatment as determined by the PI or study oncologist
- Serum creatinine ≤2.0 mg/dL
- Serum bilirubin ≤2.0 X ULN
- Serum HgB ≥8.0 mg/dL
- General
- Competent to comprehend, sign, and date an IRB-approved informed consent form
- Female subjects of childbearing potential have a negative pregnancy test
Exclusion
- Disease Related
- History or known presence of metastases
- History of another primary cancer, except:
- Curatively treated cervical carcinoma in situ, or
- Curatively resected non-melanomatous skin cancer, or
- Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ≤ 3 years prior to enrollment
- Other concurrent anticancer chemotherapy within 4 weeks as determined by the PI
- Any co-morbid disease that would increase risk of toxicity as determined by PI
- Medications/Treatments
- Subjects requiring chronic use of immunosuppressive agents (eg, methotrexate, cyclosporine, corticosteroids)
- Recent infection requiring a course of systemic anti-infectives that was completed ≤ 14 days prior to enrollment (exception can be made at the judgment of the PI for oral treatment of an uncomplicated urinary tract infection (\[UTI\])
- General
- History of any medical or psychiatric condition or addictive disorder, or laboratory abnormality that, in the opinion of the PI, may increase the risks associated with study participation or study drug administration or may interfere with the conduct of the study or interpretation of study requirements
- History of bronchospasm or severe asthma as determined by the PI
- Subject unwilling or unable to comply with study requirements
- Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection
- Documented history of alcohol, cocaine or intravenous drug abuse ≤ 6 months of enrollment
Key Trial Info
Start Date :
July 26 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 14 2015
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01878695
Start Date
July 26 2012
End Date
May 14 2015
Last Update
May 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jefferson Myrna Brind Center for Integrative Medicine
Philadelphia, Pennsylvania, United States, 19107